



**2026 Commercial Specialty Pharmacy Prior Authorization Codes
Effective 1/1/2026
(Updated April 2026)**

This list includes procedure code changes for Medical Benefit Specialty Pharmacy that may require benefit prior authorization through Blue Cross Blue Shield of Montana effective Jan. 1, 2025.

Use this document to view details for a procedure code, including:

- 1) Drug Product Name - Brand (generic)**
- 2) Reason for prior authorization where medical necessity review is required for both therapy and place of infusion (Infusion Site of Care) or for therapy only (Provider Administered Drug Therapy) and/or for Medical Oncology & Supportive Care**
- 3) Effective date for when prior authorization was implemented at BCBSMT (provider administered drug therapy or infusion site of care) or Carelon Medical Benefits Management (requests for oncology drugs that are supported by an oncology diagnosis).**

Utilization Management Process

This file is a searchable PDF.
Press "CTRL" and "F" keys at the same time to bring up the search box. Enter a procedure code or description of the service.

[For Medical Policy information, please access the BCBSMT Medical Policy Website](#)

Use this document to view details for a procedure code, including: 1) Drug Product Name - Brand (generic); 2) Reason for prior authorization where medical necessity review is required for both therapy and place of infusion (Infusion Site of Care) or for therapy only (Provider Administered Drug Therapy) and/or for Medical Oncology & Supportive Care and 3) Effective date for when prior authorization was implemented at BCBSMT (provider administered drug therapy or infusion site of care) or Carelon Medical Benefits Management (requests for oncology drugs that are supported by an oncology diagnosis).

Carelon Medical Benefits Management = Med Oncology & Supportive Care
BCBSMT = Provider Administered Therapy Or Infusion Site Of Care

Send PA requests to BCBSMT for Provider Administered Therapy or Infusion Site of Care.

Send PA requests to Carelon for Medical Oncology and Supportive care unless drug requested has multiple indications. Carelon will only review requests for oncology drugs that are supported by an oncology diagnosis. Refer to the Update History / Prior Authorization Delegation Notes for details.

Procedure Code	Service Category	Code Description	Managed By	Updates
J1553	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Immune globulin intravenous, human - dira	Carelon or BCBSMT	Add effective 7/1/2026

J1932	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection, lanreotide, (cipl), 1 mg	Carelon or BCBSMT	Add effective 7/1/2026
J3402	Provider Administered Drug Therapy	Injection, remestemcel-l-rknd, per therapeutic dose	BCBSMT	Add effective 7/1/2026
J3403	Provider Administered Drug Therapy	Revakinagene taroretcel-lwey, per implant	BCBSMT	Add effective 7/1/2026
J3404	Provider Administered Drug Therapy	Papzimeos (zopapogene imadenovec-drba)	BCBSMT	Add effective 7/1/2026
J0881	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Darbepoetin Alfa 1 Microgram (Non-Esrd Use)	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J0885	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Epoetin Alfa (For Non-Esrd Use) 1000 Units	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1459	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Privigen) Intravenous Non-Lyophilized (E.G. Liquid) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1551	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Cutaquig) 100 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1552	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection, immune globulin (alyglo), 500 mg	Carelon or BCBSMT	-
J1554	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Asceniv) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1555	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Cuvitru) 100 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.

J1556	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Bivigam) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1557	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Gammaplex) Intravenous Non-Lyophilized (E.G. Liquid) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1558	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Xembify) 100 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1559	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Hizentra) 100 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1561	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Gamunex-C/Gammaked) Non-Lyophilized (E. G. Liquid) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1566	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin Intravenous Lyophilized (E. G. Powder) Not Otherwise Specified 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1568	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Octagam) Intravenous Nonlyophilized (E.G. Liquid) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1569	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Gammagard Liquid) Non-Lyophilized (E. G. Liquid) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.

J1572	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Flebogamma/Flebogamma Dif) Intravenous Non-Lyophilized (E.G. Liquid) 500 Mg	Carelon or BCBSMT	
J1575	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin/Hyaluronidase (Hyqvia) 100 Mg Immune globulin	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1576	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Panzyga) Intravenous Non-Lyophilized (E.G. Liquid) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1599	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin Intravenous Non-Lyophilized (E.G. Liquid) Not Otherwise Specified 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1930	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Lanreotide 1 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J2353	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Octreotide Depot Form For Intramuscular Injection 1 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J9312	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Rituximab 10 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
Q5106	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Epoetin Alfa-Epbx Biosimilar (Retacrit) (For Non-Esrd Use) 1000 Units	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.

Q5115	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Rituximab-Abbs Biosimilar (Truxima) 10 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
Q5119	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Rituximab-Pvvr Biosimilar (Ruxience) 10 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
Q5123	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Rituximab-Arrx Biosimilar (Riabni) 10 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
90283	Infusion Site of Care, Provider Administered Drug Therapy	Immune Globulin (Igiv) Human For Intravenous Use	BCBSMT	-
90284	Infusion Site of Care, Provider Administered Drug Therapy	Immune Globulin (Scig) Human For Use In Subcutaneous Infusions 100 Mg Each	BCBSMT	-
J0129	Infusion Site of Care, Provider Administered Drug Therapy	Injection Abatacept 10 Mg (Code May Be Used For Medicare When Drug Administered Under The Direct Supervision Of A Physician Not For Use When Drug Is Self Administered)	BCBSMT	-
J0174	Infusion Site of Care, Provider Administered Drug Therapy	Injection, lecanemab-irmb, 1 mg	BCBSMT	Add effective 1/1/2026
J0175	Infusion Site of Care, Provider Administered Drug Therapy	Injection, donanemab-azbt, 2 mg	BCBSMT	Add effective 1/1/2026
J0180	Infusion Site of Care, Provider Administered Drug Therapy	Injection Agalsidase Beta 1 Mg	BCBSMT	-
J0218	Infusion Site of Care, Provider Administered Drug Therapy	Injection, olipudase alfa-rpcp, 1 mg	BCBSMT	Add effective 1/1/2026
J0219	Infusion Site of Care, Provider Administered Drug Therapy	Injection Avalglucosidase Alfa-Ngpt 4 Mg	BCBSMT	-

J0221	Infusion Site of Care, Provider Administered Drug Therapy	Injection Alglucosidase Alfa (Lumizyme) 10 Mg	BCBSMT	–
J0222	Infusion Site of Care, Provider Administered Drug Therapy	Injection Patisiran 0.1 Mg	BCBSMT	–
J0223	Infusion Site of Care, Provider Administered Drug Therapy	Injection, givosiran, 0.5 mg	BCBSMT	–
J0224	Infusion Site of Care, Provider Administered Drug Therapy	Injection, lumasiran, 0.5 mg	BCBSMT	–
J0225	Infusion Site of Care, Provider Administered Drug Therapy	Injection, vutrisiran, 1 mg	BCBSMT	Add effective 1/1/2026
J0485	Infusion Site of Care, Provider Administered Drug Therapy	Injection Belatacept 1 Mg	BCBSMT	–
J0490	Infusion Site of Care, Provider Administered Drug Therapy	Injection Belimumab 10 Mg	BCBSMT	–
J0491	Infusion Site of Care, Provider Administered Drug Therapy	Injection Anifrolumab-Fnia 1 Mg	BCBSMT	–
J0517	Infusion Site of Care, Provider Administered Drug Therapy	Injection Benralizumab 1 Mg	BCBSMT	–
J0584	Infusion Site of Care, Provider Administered Drug Therapy	Injection Burosumab-Twza 1 Mg	BCBSMT	–
J0598	Infusion Site of Care, Provider Administered Drug Therapy	Injection C-1 Esterase Inhibitor (Human) Cinryze 10 Units	BCBSMT	–
J0638	Infusion Site of Care, Provider Administered Drug Therapy	Injection Canakinumab 1 Mg	BCBSMT	–
J0717	Infusion Site of Care, Provider Administered Drug Therapy	Injection Certolizumab Pegol 1 Mg (Code May Be Used For Medicare When Drug Administered Under The Direct Supervision Of A Physician Not For Use When Drug Is Self Administered)	BCBSMT	–
J0791	Infusion Site of Care, Provider Administered Drug Therapy	Injection Crizanlizumab-Tmca 5 Mg	BCBSMT	–
J0888	Infusion Site of Care, Provider Administered Drug Therapy	Injection, epoetin beta, 1 microgram, (for non esrd use)	BCBSMT	Add effective 1/1/2026

J1290	Infusion Site of Care, Provider Administered Drug Therapy	Injection Ecallantide 1 Mg	BCBSMT	_
J1299	Infusion Site of Care, Provider Administered Drug Therapy	Injection, eculizumab, 2 mg	BCBSMT	_
J1301	Infusion Site of Care, Provider Administered Drug Therapy	Injection Edaravone 1 Mg	BCBSMT	_
J1302	Infusion Site of Care, Provider Administered Drug Therapy	Injection Sutimlimab-Jome 10 Mg	BCBSMT	_
J1303	Infusion Site of Care, Provider Administered Drug Therapy	Injection Ravulizumab-Cwz 10 Mg	BCBSMT	_
J1305	Infusion Site of Care, Provider Administered Drug Therapy	Injection Evinacumab-Dgnb 5Mg	BCBSMT	_
J1306	Infusion Site of Care, Provider Administered Drug Therapy	Injection Inclisiran 1 Mg	BCBSMT	_
J1322	Infusion Site of Care, Provider Administered Drug Therapy	Injection Elosulfase Alfa 1Mg	BCBSMT	_
J1458	Infusion Site of Care, Provider Administered Drug Therapy	Injection Galsulfase 1 Mg	BCBSMT	_
J1562	Infusion Site of Care, Provider Administered Drug Therapy	Injection Immune Globulin (Vivaglobin) 100 Mg	BCBSMT	Remove effective 4/1/2026
J1602	Infusion Site of Care, Provider Administered Drug Therapy	Injection Golimumab 1 Mg For Intravenous Use	BCBSMT	_
J1743	Infusion Site of Care, Provider Administered Drug Therapy	Injection Idursulfase 1 Mg	BCBSMT	_
J1745	Infusion Site of Care, Provider Administered Drug Therapy	Injection Infliximab Excludes Biosimilar 10 Mg	BCBSMT	_
J1746	Infusion Site of Care, Provider Administered Drug Therapy	Injection Ibalizumab-Uiyk 10 Mg	BCBSMT	_
J1786	Infusion Site of Care, Provider Administered Drug Therapy	Injection Imiglucerase 10 Units	BCBSMT	_
J1823	Infusion Site of Care, Provider Administered Drug Therapy	Injection Inebilizumab-Cdon 1 Mg	BCBSMT	_
J1931	Infusion Site of Care, Provider Administered Drug Therapy	Injection Laronidase 0.1 Mg	BCBSMT	_
J2182	Infusion Site of Care, Provider Administered Drug Therapy	Injection Mepolizumab 1 Mg	BCBSMT	_

J2323	Infusion Site of Care, Provider Administered Drug Therapy	Injection Natalizumab 1 Mg	BCBSMT	_
J2329	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ublituximab-xiiy, 1mg	BCBSMT	Add effective 1/1/2026
J2350	Infusion Site of Care, Provider Administered Drug Therapy	Injection Ocrelizumab 1 Mg	BCBSMT	_
J2351	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq	BCBSMT	_
J2354	Infusion Site of Care, Provider Administered Drug Therapy	Injection Octreotide Non-Depot Form For Subcutaneous Or Intravenous Injection 25 Mcg	BCBSMT	_
J2356	Infusion Site of Care, Provider Administered Drug Therapy	Injection Tezepelumab-Ekko 1 Mg	BCBSMT	_
J2357	Infusion Site of Care, Provider Administered Drug Therapy	Injection Omalizumab 5 Mg	BCBSMT	_
J2507	Infusion Site of Care, Provider Administered Drug Therapy	Injection Pegloticase 1 Mg	BCBSMT	_
J2508	Infusion Site of Care, Provider Administered Drug Therapy	Injection, pegunigalsidase alfa-iwxj, 1 mg	BCBSMT	Add effective 1/1/2026
J2786	Infusion Site of Care, Provider Administered Drug Therapy	Injection Reslizumab 1 Mg	BCBSMT	_
J2802	Infusion Site of Care, Provider Administered Drug Therapy	Injection, romiplostim, 1 microgram	BCBSMT	_
J2840	Infusion Site of Care, Provider Administered Drug Therapy	Injection Sebelipase Alfa 1 Mg	BCBSMT	_
J3032	Infusion Site of Care, Provider Administered Drug Therapy	Injection Eptinezumab-Jjmr 1 Mg	BCBSMT	_
J3060	Infusion Site of Care, Provider Administered Drug Therapy	Injection Taliglucerace Alfa 10 Units	BCBSMT	_
J3111	Infusion Site of Care, Provider Administered Drug Therapy	Injection Romosozumab-Aqqg 1 Mg	BCBSMT	_
J3241	Infusion Site of Care, Provider Administered Drug Therapy	Injection Teprotumumab-Trbw 10 Mg	BCBSMT	_
J3245	Infusion Site of Care, Provider Administered Drug Therapy	Injection Tildrakizumab 1 Mg	BCBSMT	_

J3247	Infusion Site of Care, Provider Administered Drug Therapy	Injection, secukinumab, intravenous, 1 mg	BCBSMT	Add effective 1/1/2026
J3262	Infusion Site of Care, Provider Administered Drug Therapy	Injection Tocilizumab 1 Mg	BCBSMT	–
J3358	Infusion Site of Care, Provider Administered Drug Therapy	Ustekinumab For Intravenous Injection 1 Mg	BCBSMT	–
J3380	Infusion Site of Care, Provider Administered Drug Therapy	Injection Vedolizumab Intravenous 1 Mg	BCBSMT	–
J3385	Infusion Site of Care, Provider Administered Drug Therapy	Injection Velaglucerase Alfa 100 Units	BCBSMT	–
J3397	Infusion Site of Care, Provider Administered Drug Therapy	Injection Vestronidase Alfa-Vjvk 1 Mg	BCBSMT	–
J7183	Infusion Site of Care, Provider Administered Drug Therapy	Injection Von Willebrand Factor Complex (Human) Wilate 1 I.U. Vwf:Rco	BCBSMT	–
J9256	Infusion Site of Care, Provider Administered Drug Therapy	Imaavy (nipocalimab-aahu)	BCBSMT	Add effective 4/1/2026
J9332	Infusion Site of Care, Provider Administered Drug Therapy	Injection Efgartigimod Alfa-Fcab 2Mg	BCBSMT	–
J9333	Infusion Site of Care, Provider Administered Drug Therapy	Injection, rozanolixumab-noli, 1 mg	BCBSMT	Add effective 1/1/2026
J9334	Infusion Site of Care, Provider Administered Drug Therapy	Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc	BCBSMT	Add effective 1/1/2026
J9376	Infusion Site of Care, Provider Administered Drug Therapy	Injection, pozelimab-bbfg, 1 mg	BCBSMT	Add effective 1/1/2026
Q5098	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg	BCBSMT	–
Q5099	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg	BCBSMT	–
Q5100	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg	BCBSMT	–
Q5103	Infusion Site of Care, Provider Administered Drug Therapy	Injection Infliximab-Dyyb Biosimilar (Inflectra) 10 Mg	BCBSMT	–
Q5104	Infusion Site of Care, Provider Administered Drug Therapy	Injection Infliximab-Abda Biosimilar (Renflexis) 10 Mg	BCBSMT	–

Q5109	Infusion Site of Care, Provider Administered Drug Therapy	Injection Infliximab-Qbtx Biosimilar (Ixifi) 10 Mg	BCBSMT	Remove effective 4/1/2026
Q5121	Infusion Site of Care, Provider Administered Drug Therapy	Injection Infliximab-Axxq Biosimilar (Avsola) 10 Mg	BCBSMT	–
Q5133	Infusion Site of Care, Provider Administered Drug Therapy	Injection, Tocilizumab-Bavi (Tofidence), Biosimilar, 1 Mg	BCBSMT	–
Q5134	Infusion Site of Care, Provider Administered Drug Therapy	Injection, Natalizumab-Sztn (Tyruko), Biosimilar, 1 Mg	BCBSMT	–
Q5135	Infusion Site of Care, Provider Administered Drug Therapy	Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg	BCBSMT	–
Q5138	Infusion Site of Care, Provider Administered Drug Therapy	ustekinumab-auub	BCBSMT	–
Q5151	Infusion Site of Care, Provider Administered Drug Therapy	Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg	BCBSMT	–
Q5152	Infusion Site of Care, Provider Administered Drug Therapy	Injection, eculizumab-aeab (bkemv), biosimilar, 2 mg	BCBSMT	–
Q5154	Infusion Site of Care, Provider Administered Drug Therapy	Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg	BCBSMT	Add effective 1/1/2026
Q5156	Infusion Site of Care, Provider Administered Drug Therapy	Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg	BCBSMT	Add effective 1/1/2026
Q9997	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg	BCBSMT	–
Q9998	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ustekinumab-aeqn (selarsdi), 1 mg	BCBSMT	–
Q9999	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg	BCBSMT	–

C9399	Medical Oncology & Supportive Care	Unclassified Drugs Or Biologicals	Carelon	Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Unituxin (Dinutuximab). Add effective 07/01/24: Avzivi (bevacizumab-tjnj). Add new drugs effective 10/01/25: bevacizumab-nwgd [This drug to be reviewed under Q5160 effective 04/1/26], penpulimab-kcqx, Add effective 01/01/26: Emrelis (telisotuzumab vedotin-tllv)[This drug to be reviewed under J9326 effective 04/1/26], Zsduri (mitomycin) [This drug to be reviewed under J9282 effective 04/1/26], Linozyfic (linvoseltamab-gcpt) [This drug to be reviewed under J9601 effective 04/1/26]. Add effective 04/01/26: Qivigy (immune globulin intravenous, human-kthm), Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph)[This drug to be reviewed under J9277 effective 04/1/26], Inlexzo (gemcitabine intravesical system)[This drug to be reviewed under J9183 effective 04/1/26] , Blenrep (belantamab mafodotin-blmf), Poherdy (pertuzumab-dpzb), Bilyos/Bilprevda (denosumab-nxxp)[This drug to be reviewed under Q5162 effective 04/1/26], Enoby/Xtrenbo (denosumab-qbde), Bosaya/Aukelso (denosumab-kyqq)[This drug to be reviewed under Q5161 effective 04/1/26], Osvyrti/Jubereq (denosumab-desu) Add new drugs effective 7/1/26: Armlupeg (pegfilgrastim-unne), Filkri (filgrastim-laha), Rybrevant Faspro (amivantamab/hyaluronidase-lpuj), Lunsumio Velo (mosunetuzumab-axgb), Boncresa/Oziltus (denosumab-mobz), Gammagard ERC (immune globulin infusion (human))
J0642	Medical Oncology & Supportive Care	Injection Levoleucovorin (Khazory) 0.5 Mg	Carelon	-
J0870	Medical Oncology & Supportive Care	Imetelstat (Rytelo)	Carelon	-
J0882	Medical Oncology & Supportive Care	Injection Darbepoetin Alfa 1 Microgram (For Esrd On Dialysis)	Carelon	-

J0896	Medical Oncology & Supportive Care	Injection Luspatercept-Aamt 0.25 Mg	Carelon	_
J0897	Medical Oncology & Supportive Care	Injection Denosumab 1 Mg	Carelon	_
J1323	Medical Oncology & Supportive Care	Injection Elranatamab-Bcmm 1 Mg	Carelon	_
J1326	Medical Oncology & Supportive Care	Vyloy (zolbetuximab-clzb)	Carelon	_
J1442	Medical Oncology & Supportive Care	Injection Filgrastim (G-Csf) Excludes Biosimilars 1 Microgram	Carelon	_
J1447	Medical Oncology & Supportive Care	Injection Tbo-Filgrastim 1 Microgram	Carelon	_
J1448	Medical Oncology & Supportive Care	Injection Trilaciclib 1Mg	Carelon	_
J1449	Medical Oncology & Supportive Care	Injection Eflapegrastim-Xnst 0.1 Mg	Carelon	_
J2506	Medical Oncology & Supportive Care	Injection Pegfilgrastim Excludes Biosimilar 0.5 Mg	Carelon	_
J2820	Medical Oncology & Supportive Care	Injection Sargramostim (Gm- Csf) 50 Mcg	Carelon	_
J2860	Medical Oncology & Supportive Care	Injection Siltuximab 10 Mg	Carelon	_
J3055	Medical Oncology & Supportive Care	Injection Talquetamab-Tgvs 0.25 Mg	Carelon	_
J3263	Medical Oncology & Supportive Care	Loqtorzi (toripalimab-tpzi)	Carelon	_

J3490	Medical Oncology & Supportive Care	Unclassified Drugs	Carelon	Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Unituxin (Dinutuximab). Add effective 07/01/24: Avzivi (bevacizumab-tnjn). Add new drugs effective 10/01/25: bevacizumab-nwgd [This drug to be reviewed under Q5160 effective 04/1/26], penpulimab-kcqx, Add effective 01/01/26: Emrelis (telisotuzumab vedotin-tllv)[This drug to be reviewed under J9326 effective 04/1/26], Zusduri (mitomycin) [This drug to be reviewed under J9282 effective 04/1/26], Lynozyfic (linvoseltamab-gcpt) [This drug to be reviewed under J9601 effective 04/1/26]. Add effective 04/01/26: Qivigy (immune globulin intravenous, human-kthm), Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph)[This drug to be reviewed under J9277 effective 04/1/26], Inlexzo (gemcitabine intravesical system)[This drug to be reviewed under J9183 effective 04/1/26] , Blenrep (belantamab mafodotin-blmf), Poherdy (pertuzumab-dpzb), Bldyos/Bilprevda (denosumab-nxxp)[This drug to be reviewed under Q5162 effective 04/1/26], Enoby/Xtrenbo (denosumab-qbde), Bosaya/Aukelso (denosumab-kyqq)[This drug to be reviewed under Q5161 effective 04/1/26], Osvyrti/Jubereq (denosumab-desu) Add new drugs effective 7/1/26: Armlupeg (pegfilgrastim-unne), Filkri (filgrastim-laha), Rybrevant Faspro (amivantamab/hyaluronidase-lpuj), Lunsumio Velo (mosunetuzumab-axgb), Boncresa/Oziltus (denosumab-mobz), Gammagard ERC (immune globulin infusion (human))
-------	------------------------------------	--------------------	---------	--

J3590	Medical Oncology & Supportive Care	Unclassified Biologics	Carelon	Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Unituxin (Dinutuximab). Add effective 07/01/24: Avzivi (bevacizumab-tjnj). Add new drugs effective 10/01/25: bevacizumab-nwgd [This drug to be reviewed under Q5160 effective 04/1/26], penpulimab-kcqx, Add effective 01/01/26: Emrelis (telisotuzumab vedotin-tllv)[This drug to be reviewed under J9326 effective 04/1/26], Zsduri (mitomycin) [This drug to be reviewed under J9282 effective 04/1/26], Lynozyfic (linvoseltamab-gcpt) [This drug to be reviewed under J9601 effective 04/1/26]. Add effective 04/01/26: Qivigy (immune globulin intravenous, human-kthm), Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph)[This drug to be reviewed under J9277 effective 04/1/26], Inlexzo (gemcitabine intravesical system)[This drug to be reviewed under J9183 effective 04/1/26] , Blenrep (belantamab mafodotin-blmf), Poherdy (pertuzumab-dpzb), Bilyos/Bilprevda (denosumab-nxxp)[This drug to be reviewed under Q5162 effective 04/1/26], Enoby/Xtrenbo (denosumab-qbde), Bosaya/Aukelso (denosumab-kyqq)[This drug to be reviewed under Q5161 effective 04/1/26], Osvyrti/Jubereq (denosumab-desu) Add new drugs effective 7/1/26: Armlupeq (pegfilgrastim-unne),Filkri (filgrastim-laha),Rybrevent Faspro (amivantamab/hyaluronidase-lpuj),Lunsumio Velo (mosunetuzumab-axgb),Boncresa/Oziltus (denosumab-mobz),Gammagard ERC (immune globulin infusion (human))
J9011	Medical Oncology & Supportive Care	Injection, datopotamab deruxtecan-dlnk, 1 mg	Carelon	Add effective 1/1/2026
J9019	Medical Oncology & Supportive Care	Injection Asparaginase (Erwinaze) 1 000 lu	Carelon	Remove effective 4/1/2026
J9021	Medical Oncology & Supportive Care	Injection Asparaginase Recombinant (Rylaze) 0.1 Mg	Carelon	_
J9022	Medical Oncology & Supportive Care	Injection Atezolizumab 10 Mg	Carelon	_

J9023	Medical Oncology & Supportive Care	Injection Avelumab 10 Mg	Carelon	_
J9024	Medical Oncology & Supportive Care	Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)	Carelon	_
J9026	Medical Oncology & Supportive Care	Injection, tarlatamab-dlle, 1 mg	Carelon	_
J9028	Medical Oncology & Supportive Care	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram	Carelon	_
J9032	Medical Oncology & Supportive Care	Injection Belinostat 10 Mg	Carelon	_
J9035	Medical Oncology & Supportive Care	Injection Bevacizumab 10 Mg	Carelon	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis.
J9039	Medical Oncology & Supportive Care	Injection Blinatumomab 1 Microgram	Carelon	_
J9042	Medical Oncology & Supportive Care	Injection Brentuximab Vedotin 1 Mg	Carelon	_
J9043	Medical Oncology & Supportive Care	Injection Cabazitaxel 1 Mg	Carelon	_
J9047	Medical Oncology & Supportive Care	Injection Carfilzomib 1 Mg	Carelon	_
J9055	Medical Oncology & Supportive Care	Injection Cetuximab 10 Mg	Carelon	_
J9061	Medical Oncology & Supportive Care	Injection Amivantamab-Vmjw 2 Mg	Carelon	_
J9063	Medical Oncology & Supportive Care	Injection Mirvetuximab Soravtansine-Gynx 1 Mg	Carelon	_
J9064	Medical Oncology & Supportive Care	Injection Cabazitaxel (Sandoz) Not Therapeutically Equivalent To J9043 1 Mg	Carelon	_
J9118	Medical Oncology & Supportive Care	Injection Calaspargase Pegol-Mknl 10 Units	Carelon	_
J9119	Medical Oncology & Supportive Care	Injection Cemiplimab-Rwlc 1 Mg	Carelon	_
J9144	Medical Oncology & Supportive Care	Injection Daratumumab 10 Mg And Hyaluronidase-Fihj	Carelon	_
J9145	Medical Oncology & Supportive Care	Injection Daratumumab 10 Mg	Carelon	_

J9153	Medical Oncology & Supportive Care	Injection Liposomal 1 Mg Daunorubicin And 2.27 Mg Cytarabine	Carelon	_
J9161	Medical Oncology & Supportive Care	Lymphir (denileukin diftitox-cxdl)	Carelon	_
J9173	Medical Oncology & Supportive Care	Injection Durvalumab 10 Mg	Carelon	_
J9176	Medical Oncology & Supportive Care	Injection Elotuzumab 1 Mg	Carelon	_
J9177	Medical Oncology & Supportive Care	Injection Enfortumab Vedotin-Ejfv 0.25 Mg	Carelon	_
J9179	Medical Oncology & Supportive Care	Injection Eribulin Mesylate 0.1 Mg	Carelon	_
J9183	Medical Oncology & Supportive Care	Inlexzo (gemcitabine intravesical system)	Carelon	Add effective 4/1/2026
J9203	Medical Oncology & Supportive Care	Injection Gemtuzumab Ozogamicin 0.1 Mg	Carelon	_
J9204	Medical Oncology & Supportive Care	Injection Mogamulizumab-Kpkc 1 Mg	Carelon	_
J9205	Medical Oncology & Supportive Care	Injection Irinotecan Liposome 1 Mg	Carelon	_
J9207	Medical Oncology & Supportive Care	Injection Ixabepilone 1 Mg	Carelon	_
J9223	Medical Oncology & Supportive Care	Injection Lurbinectedin 0.1 Mg	Carelon	_
J9227	Medical Oncology & Supportive Care	Injection Isatuximab-lrfc 10 Mg	Carelon	_
J9228	Medical Oncology & Supportive Care	Injection Ipilimumab 1 Mg	Carelon	_
J9229	Medical Oncology & Supportive Care	Injection Inotuzumab Ozogamicin 0.1 Mg	Carelon	_
J9264	Medical Oncology & Supportive Care	Injection Paclitaxel Protein-Bound Particles 1 Mg	Carelon	_
J9266	Medical Oncology & Supportive Care	Injection Pegaspargase Per Single Dose Vial	Carelon	_
J9269	Medical Oncology & Supportive Care	Injection Tagraxofusp-Erzs 10 Micrograms	Carelon	_
J9271	Medical Oncology & Supportive Care	Injection Pembrolizumab 1 Mg	Carelon	_

J9272	Medical Oncology & Supportive Care	Injection Dostarlimab-Gxly 10 Mg	Carelon	_
J9273	Medical Oncology & Supportive Care	Injection Tisotumab Vedotin-Tftv 1 Mg	Carelon	_
J9274	Medical Oncology & Supportive Care	Injection Tebentafusp-Tebn 1 Microgram	Carelon	_
J9275	Medical Oncology & Supportive Care	Untoxcyt (cosibelimab-ipdl)	Carelon	_
J9276	Medical Oncology & Supportive Care	Ziihera (zanidatamab-hrii)	Carelon	_
J9277	Medical Oncology & Supportive Care	Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph)	Carelon	Add effective 4/1/2026
J9281	Medical Oncology & Supportive Care	Mitomycin Pyelocalyceal Instillation 1 Mg	Carelon	_
J9282	Medical Oncology & Supportive Care	mitomycin	Carelon	Add effective 4/1/2026
J9286	Medical Oncology & Supportive Care	Injection Glofitamab-Gxbm 2.5 Mg	Carelon	_
J9289	Medical Oncology & Supportive Care	Opdivo Qvantig (nivolumab hyaluronidase-nvhy)	Carelon	_
J9295	Medical Oncology & Supportive Care	Injection Necitumumab 1 Mg	Carelon	_
J9298	Medical Oncology & Supportive Care	Injection Nivolumab And Relatlimab-Rmbw 3 Mg/1 Mg	Carelon	_
J9299	Medical Oncology & Supportive Care	Injection Nivolumab 1 Mg	Carelon	_
J9302	Medical Oncology & Supportive Care	Injection Ofatumumab 10 Mg	Carelon	_
J9303	Medical Oncology & Supportive Care	Injection Panitumumab 10 Mg	Carelon	_
J9306	Medical Oncology & Supportive Care	Injection Pertuzumab 1 Mg	Carelon	_
J9308	Medical Oncology & Supportive Care	Injection Ramucirumab 5 Mg	Carelon	_
J9309	Medical Oncology & Supportive Care	Injection Polatuzumab Vedotin-Piiq 1 Mg	Carelon	_
J9311	Medical Oncology & Supportive Care	Injection Rituximab 10 Mg And Hyaluronidase	Carelon	_
J9316	Medical Oncology & Supportive Care	Injection Pertuzumab Trastuzumab And Hyaluronidase-Zzxf Per 10 Mg	Carelon	_
J9317	Medical Oncology & Supportive Care	Injection Sacituzumab Govitecan-Hziy 2.5 Mg	Carelon	_

J9321	Medical Oncology & Supportive Care	Injection Epcoritamab-Bysp 0.16 Mg	Carelon	_
J9325	Medical Oncology & Supportive Care	Injection Talimogene Laherparepvec Per 1 Million Plaque Forming Units	Carelon	_
J9326	Medical Oncology & Supportive Care	telisotuzumab vedotin-tllv	Carelon	Add effective 4/1/2026
J9329	Medical Oncology & Supportive Care	Injection, tislelizumab-jsgr, 1mg	Carelon	_
J9331	Medical Oncology & Supportive Care	Injection Sirolimus Protein- Bound Particles 1 Mg	Carelon	_
J9345	Medical Oncology & Supportive Care	Injection Retifanimab-Dlwr 1 Mg	Carelon	_
J9347	Medical Oncology & Supportive Care	Injection Tremelimumab-Actl 1 Mg	Carelon	_
J9348	Medical Oncology & Supportive Care	Injection Naxitamab-Gqgk 1 Mg	Carelon	_
J9349	Medical Oncology & Supportive Care	Injection Tafasitamab-Cxix 2 Mg	Carelon	_
J9350	Medical Oncology & Supportive Care	Injection Mosunetuzumab-Axgb 1 Mg	Carelon	_
J9352	Medical Oncology & Supportive Care	Injection Trabectedin 0.1 Mg	Carelon	_
J9353	Medical Oncology & Supportive Care	Injection Margetuximab-Cmkb 5 Mg	Carelon	_
J9354	Medical Oncology & Supportive Care	Injection Ado-Trastuzumab Emtansine 1 Mg	Carelon	_
J9355	Medical Oncology & Supportive Care	Injection Trastuzumab Excludes Biosimilar 10 Mg	Carelon	_
J9356	Medical Oncology & Supportive Care	Injection Trastuzumab 10 Mg And Hyaluronidase-Oysk	Carelon	_
J9358	Medical Oncology & Supportive Care	Injection Fam-Trastuzumab Deruxtecan-Nxki 1 Mg	Carelon	_
J9359	Medical Oncology & Supportive Care	Injection Loncastuximab Tesirine-Lpyl 0.075 Mg	Carelon	_
J9361	Medical Oncology & Supportive Care	Ryzneuta (efbemalenograstim alfa-vuxw)	Carelon	_

J9380	Medical Oncology & Supportive Care	Injection Teclistamab-Cqyv 0.5 Mg	Carelon	-
J9382	Medical Oncology & Supportive Care	Bizengri (zenocutuzumab-zbco)	Carelon	-
J9601	Medical Oncology & Supportive Care	Lynozyfic (linvoseltamab-gcpt)	Carelon	Add effective 4/1/2026
J9999	Medical Oncology & Supportive Care	Not Otherwise Classified Antineoplastic Drugs	Carelon	Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Unituxin (Dinutuximab). Add effective 07/01/24: Avzivi (bevacizuman-tjnj). Add new drugs effective 10/01/25: bevacizumab-nwgd [This drug to be reviewed under Q5160 effective 04/1/26], penpulimab-kcqx, Add effective 01/01/26: Emrelis (telisotuzumab vedotin-tllv)[This drug to be reviewed under J9326 effective 04/1/26], Zsduri (mitomycin) [This drug to be reviewed under J9282 effective 04/1/26], Lynozyfic (linvoseltamab-gcpt) [This drug to be reviewed under J9601 effective 04/1/26]. Add effective 04/01/26: Qivigy (immune globulin intravenous, human-kthm), Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph)[This drug to be reviewed under J9277 effective 04/1/26], Intexzo (gemcitabine intravesical system)[This drug to be reviewed under J9183 effective 04/1/26], Blenrep (belantamab mafodotin-blmf), Poherdy (pertuzumab-dpzb), Bilyos/Bilprevda (denosumab-nxxp)[This drug to be reviewed under Q5162 effective 04/1/26], Enoby/Xtrenbo (denosumab-qbde), Bosaya/Aukelso (denosumab-kyqq)[This drug to be reviewed under Q5161 effective 04/1/26], Osvyrti/Jubereq (denosumab-desu) Add new drugs effective 7/1/26: Armlupeg (pegfilgrastim-unne), Filkri (filgrastim-laha), Rybrevant Faspro (amivantamab/hyaluronidase-lpuj), Lunsumio Velo (mosunetuzumab-axgb), Boncresa/Oziltus (denosumab-mobz), Gammagard ERC (immune globulin infusion (human))

Q2043	Medical Oncology & Supportive Care	Sipuleucel-T Minimum Of 50 Million Autologous Cd54+ Cells Activated With Pap-Gm-Csf Including Leukapheresis And All Other Preparatory Procedures Per Infusion	Carelon	-
Q2050	Medical Oncology & Supportive Care	Injection Doxorubicin Hydrochloride Liposomal Not Otherwise Specified 10Mg	Carelon	-
Q4081	Medical Oncology & Supportive Care	Injection Epoetin Alfa 100 Units (For Esrd On Dialysis)	Carelon	-
Q5101	Medical Oncology & Supportive Care	Injection Filgrastim-Sndz Biosimilar (Zarxio) 1 Microgram	Carelon	-
Q5105	Medical Oncology & Supportive Care	Injection Epoetin Alfa-Epbx Biosimilar (Retacrit) (For Esrd On Dialysis) 100 Units	Carelon	-
Q5107	Medical Oncology & Supportive Care	Injection Bevacizumab-Awwb Biosimilar (Mvasi) 10 Mg	Carelon	-
Q5108	Medical Oncology & Supportive Care	Injection Pegfilgrastim-Jmdb (Fulphila) Biosimilar 0.5 Mg	Carelon	-
Q5110	Medical Oncology & Supportive Care	Injection Filgrastim-Aafi Biosimilar (Nivestym) 1 Microgram	Carelon	-
Q5111	Medical Oncology & Supportive Care	Injection Pegfilgrastim-Cbqv (Udenyca) Biosimilar 0.5 Mg	Carelon	-
Q5112	Medical Oncology & Supportive Care	Injection Trastuzumab-Dttb Biosimilar (Ontruzant) 10 Mg	Carelon	-
Q5113	Medical Oncology & Supportive Care	Injection Trastuzumab-Pkrb Biosimilar (Herzuma) 10 Mg	Carelon	-
Q5114	Medical Oncology & Supportive Care	Injection Trastuzumab-Dkst Biosimilar (Ogivri) 10 Mg	Carelon	-
Q5116	Medical Oncology & Supportive Care	Injection Trastuzumab-Qyyp Biosimilar (Trazimera) 10 Mg	Carelon	-
Q5117	Medical Oncology & Supportive Care	Injection Trastuzumab-Anns Biosimilar (Kanjinti) 10 Mg	Carelon	-

Q5118	Medical Oncology & Supportive Care	Injection Bevacizumab-Bvzr Biosimilar (Zirabev) 10 Mg	Carelon	_
Q5120	Medical Oncology & Supportive Care	Injection Pegfilgrastim-Bmez (Ziextenzo) Biosimilar 0.5 Mg	Carelon	_
Q5122	Medical Oncology & Supportive Care	Injection Pegfilgrastim-Apgf (Nyvepria) Biosimilar 0.5 Mg	Carelon	_
Q5125	Medical Oncology & Supportive Care	Injection Filgrastim-Ayow Biosimilar (Releuko) 1 Microgram	Carelon	_
Q5126	Medical Oncology & Supportive Care	Injection Bevacizumab-Maly Biosimilar (Alymsys) 10 Mg	Carelon	_
Q5127	Medical Oncology & Supportive Care	Injection Pegfilgrastim-Fpgk (Stimufend) Biosimilar 0.5 Mg	Carelon	_
Q5129	Medical Oncology & Supportive Care	Injection Bevacizumab-Adcd (Vegzelma) Biosimilar 10 Mg	Carelon	_
Q5130	Medical Oncology & Supportive Care	Injection Pegfilgrastim-Pbbk (Fylnetra) Biosimilar 0.5 Mg	Carelon	_
Q5136	Medical Oncology & Supportive Care	Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg	Carelon	_
Q5146	Medical Oncology & Supportive Care	Trastuzumab-strf (Hercessi)	Carelon	_
Q5148	Medical Oncology & Supportive Care	Nypozi (filgrastim-txid)	Carelon	_
Q5157	Medical Oncology & Supportive Care	Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg	Carelon	Add effective 1/1/2026
Q5158	Medical Oncology & Supportive Care	Injection, denosumab-bnht (bomynta/conexence), biosimilar, 1 mg	Carelon	Add effective 1/1/2026
Q5159	Medical Oncology & Supportive Care	Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg	Carelon	Add effective 1/1/2026
Q5160	Medical Oncology & Supportive Care	bevacizumab-nwgd	Carelon	Add effective 4/1/2026
Q5161	Medical Oncology & Supportive Care	Bosaya/Aukelso (denosumab-kyqq)	Carelon	Add effective 4/1/2026
Q5162	Medical Oncology & Supportive Care	Bildyos/Bilprevda (denosumab-nxxp)	Carelon	Add effective 4/1/2026

J9301	Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Obinutuzumab 10 Mg	Carelon	Add to Provider Administered Drug Therapy Category effective 4/1/26. Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J0202	Provider Administered Drug Therapy	Injection Alemtuzumab 1 Mg	BCBSMT	-
J0567	Provider Administered Drug Therapy	Injection Cerliponase Alfa 1 Mg	BCBSMT	-
J0585	Provider Administered Drug Therapy	Injection Onabotulinumtoxina 1 Unit	BCBSMT	-
J0586	Provider Administered Drug Therapy	Injection Abobotulinumtoxina 5 Units	BCBSMT	-
J0587	Provider Administered Drug Therapy	Injection Rimabotulinumtoxina 100 Units	BCBSMT	-
J0588	Provider Administered Drug Therapy	Injection Incobotulinumtoxin A 1 Unit	BCBSMT	-
J0589	Provider Administered Drug Therapy	Injection, Daxibotulinumtoxina-Lanm, 1 Unit	BCBSMT	-
J0741	Provider Administered Drug Therapy	Injection Cabotegravir And Rilpivirine 2Mg/3Mg	BCBSMT	-
J0775	Provider Administered Drug Therapy	Injection Collagenase Clostridium Histolyticum 0.01 Mg	BCBSMT	-
J1203	Provider Administered Drug Therapy	Injection, Cipaglucosidase Alfa-Atga, 5 Mg	BCBSMT	-
J1304	Provider Administered Drug Therapy	Injection, Tofersen, 1 Mg	BCBSMT	-
J1307	Provider Administered Drug Therapy	Injection, crovalimab-akkz, 10 mg	BCBSMT	-
J1411	Provider Administered Drug Therapy	Injection Etranacogene Dezaparvovec-Drlb Per Therapeutic Dose	BCBSMT	-

J1412	Provider Administered Drug Therapy	Injection Valoctocogene Roxaparvovec-Rvox Per Ml Containing Nominal 2 X 10 ¹³ Vector Genomes	BCBSMT	-
J1413	Provider Administered Drug Therapy	Injection Delandistrogene Moxeparvovec-Rokl Per Therapeutic Dose	BCBSMT	-
J1426	Provider Administered Drug Therapy	Injection, Casimersen, 10 Mg	BCBSMT	-
J1427	Provider Administered Drug Therapy	Injection, Viltolarsen, 10 Mg	BCBSMT	-
J1428	Provider Administered Drug Therapy	Injection Eteplirsen 10 Mg	BCBSMT	-
J1429	Provider Administered Drug Therapy	Injection, Golodirsen, 10 Mg	BCBSMT	-
J1628	Provider Administered Drug Therapy	Injection, guselkumab, 1 mg	BCBSMT	-
J1747	Provider Administered Drug Therapy	Injection, Spesolimab-Sbzo, 1 Mg	BCBSMT	-
J1961	Provider Administered Drug Therapy	Injection Lenacapavir 1 Mg	BCBSMT	-
J2267	Provider Administered Drug Therapy	mirikizumab-mrkz	BCBSMT	-
J2326	Provider Administered Drug Therapy	Injection Nusinersen 0.1 Mg	BCBSMT	-
J2327	Provider Administered Drug Therapy	Injection, Risankizumab-Rzaa, Intravenous, 1 Mg	BCBSMT	-
J2941	Provider Administered Drug Therapy	Injection Somatropin 1 Mg	BCBSMT	-
J3387	Provider Administered Drug Therapy	Skysona (elivaldogene autotemcel)	BCBSMT	Add effective 4/1/2026
J3389	Provider Administered Drug Therapy	Zevaskyn (prademagene zamikeracel)	BCBSMT	Add effective 4/1/2026
J3391	Provider Administered Drug Therapy	Injection, atidarsagene autotemcel, per treatment	BCBSMT	-
J3392	Provider Administered Drug Therapy	Injection, exagamglogene autotemcel, per treatment	BCBSMT	-
J3393	Provider Administered Drug Therapy	Injection, betibeglogene autotemcel, per treatment	BCBSMT	-
J3394	Provider Administered Drug Therapy	Injection, lovitibeglogene autotemcel, per treatment	BCBSMT	-
J3398	Provider Administered Drug Therapy	Injection Voretigene Neparvovec-Rzyl 1 Billion Vector Genomes	BCBSMT	-

J3399	Provider Administered Drug Therapy	Injection Onasemnogene Abeparvovec-Xioi Per Treatment Up To 5X10 ¹⁵ Vector Genomes	BCBSMT	-
J3401	Provider Administered Drug Therapy	Beremagene Geperpavec-Svdt For Topical Administration Containing Nominal 5 X 10 ⁹ Pfu/ML Vector Genomes Per 0.1 ML	BCBSMT	-
J9029	Provider Administered Drug Therapy	Intravesical Instillation Nadofaragene Firadenovec-Vncg Per Therapeutic Dose	BCBSMT	-
Q2041	Provider Administered Drug Therapy	Axicabtagene Ciloleucel Up To 200 Million Autologous Anti-Cd19 Car Positive Viable T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose	BCBSMT	-
Q2042	Provider Administered Drug Therapy	Tisagenlecleucel Up To 600 Million Car-Positive Viable T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose	BCBSMT	-
Q2053	Provider Administered Drug Therapy	Brexucabtagene Autoleucel Up To 200 Million Autologous Anti-Cd19 Car Positive Viable T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose	BCBSMT	-

Q2054	Provider Administered Drug Therapy	Lisocabtagene Maraleucel Up To 110 Million Autologous Anti-Cd19 Car-Positive Viable T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose	BCBSMT	-
Q2055	Provider Administered Drug Therapy	Idecabtagene Vicleucel Up To 460 Million Autologous B-Cell Maturation Antigen (Bcma) Directed Car-Positive T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose	BCBSMT	-
Q2056	Provider Administered Drug Therapy	Ciltacabtagene Autoleucel Up To 100 Million Autologous B-Cell Maturation Antigen (Bcma) Directed Car-Positive T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose	BCBSMT	-
Q2057	Provider Administered Drug Therapy	Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose	BCBSMT	-
Q2058	Provider Administered Drug Therapy	Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion	BCBSMT	-

Important Notes:

CPT copyright 2025 American Medical Association. All rights reserved. CPT is a registered trademark of the AMA.

Please note that checking eligibility and benefits and/or the fact that a service has received prior authorization is not a guarantee of payment. Benefits will be determined once a claim is received and will be based upon, among other things, the member's eligibility and the terms of the member's certificate of coverage applicable on the date services were rendered. The information provided does not constitute coding or legal advice. Physicians and other health care providers should use their own medical judgment based upon all available information and the condition of the patient in determining the appropriate course of treatment, and to submit claims using the most appropriate code(s) based upon the medical record documentation, coding guidelines and reference materials.

Availity is a trademark of Availity, LLC, a separate company that operates a health information network to provide electronic information exchange services to medical professionals. Availity provides administrative services to BCBSMT.

Carelon Medical Benefits Management is an independent company that has contracted with BCBSMT to provide utilization management services for members with coverage through BCBSMT.

BCBSMT makes no endorsement, representations or warranties regarding any products or services provided by third party vendors such as Availity or Carelon Medical Benefits Management. Please contact the vendor(s) directly for any questions regarding products or services offered.

Blue Cross and Blue Shield of Montana, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association.▪